Brief: Oric Pharmaceuticals Announces Clinical Development Collaboration With Pfizer For Oric-533 In Multiple Myeloma And Concurrent $25 Million Equity Investment By Pfizer

ORIC Pharmaceuticals

21/12/2022 22:31

Dec 21 (Reuters) - Oric Pharmaceuticals Inc  ORIC.O :
    * ORIC PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT
COLLABORATION WITH PFIZER FOR ORIC-533 IN MULTIPLE MYELOMA AND
CONCURRENT $25 MILLION EQUITY INVESTMENT BY PFIZER
    * ORIC PHARMACEUTICALS INC- JEFF SETTLEMAN, PH.D., CHIEF
SCIENTIFIC OFFICER, PFIZER ONCOLOGY, TO JOIN ORIC SCIENTIFIC
ADVISORY BOARD
    * ORIC PHARMACEUTICALS INC- INCLUDING $25 MILLION EQUITY
INVESTMENT FROM PFIZER, ORIC CASH RUNWAY EXTENDED INTO 1H 2025
    * ORIC PHARMACEUTICALS- CO, PFIZER ENTER CLINICAL
DEVELOPMENT
COLLABORATION FOR PHASE 2 STUDY OF ORIC-533 IN COMBINATION WITH
ELRANATAMAB IN MULTIPLE MYELOMA

Further company coverage:  ORIC.O 
 ((Reuters.Briefs@thomsonreuters.com;))